Admission hyperglycemia effect on symptomatic intracranial hemorrhage in tenecteplase versus alteplase before large vessel occlusion stroke thrombectomy

J Neurol. 2024 Dec;271(12):7605-7612. doi: 10.1007/s00415-024-12704-7. Epub 2024 Sep 23.

Abstract

Introduction: Intravenous thrombolysis (IVT) with alteplase (TPA) in hyperglycemic stroke patients is associated with an increased risk of symptomatic intracranial hemorrhage (sICH) and poor functional outcomes. We aimed to explore the association between admission hyperglycemia and sICH in large vessel occlusion stroke (LVOS) patients treated with TNK versus TPA before endovascular thrombectomy (EVT).

Methods: We reviewed consecutive LVOS patients treated with TPA or TNK before EVT from 01/2020 to 06/2023. EVT was performed across five comprehensive stroke centers (CSCs) in Pennsylvania. Of 569 patients, 462 met inclusion criteria: LVOS, pre-stroke modified Rankin Scale (mRS) 0-2, and last-known-well to IVT (LKW-to-IVT) ≤ 4.5 h. The rates of sICH and parenchymal hematomas (PHs) between TPA and TNK cohorts were assessed.

Results: Of 462 patients, 254 (55%) received TNK, and 208 (45%) received TPA. Admission hyperglycemia (≥ 140 mg/dl) was present in 153 (33.1%) patients. Hyperglycemic patients were more frequently diabetic (p < 0.001). Admission hyperglycemia was associated with a significantly increased rate of sICH (5.9% versus 1.6%, p = 0.019) and PH (20.3% versus 11.3%, p = 0.010). Hyperglycemic patients had a significantly higher degree of overall disability as compared to normoglycemic patients (90d-mRS shift aOR 0.611, p = 0.007). Comparable rates of sICH and PH were observed in the hyperglycemic and normoglycemic cohorts among both TNK and TPA groups.

Conclusion: In LVOS patients receiving IVT before EVT, admission hyperglycemia significantly increased the risk of sICH and PH and was associated with worse outcomes at 90 days. No differences in sICH or PH were observed between TNK and TPA groups.

Keywords: Alteplase; Hyperglycemia; Symptomatic intracranial hemorrhage; Tenecteplase.

Publication types

  • Comparative Study

MeSH terms

  • Aged
  • Aged, 80 and over
  • Endovascular Procedures / adverse effects
  • Female
  • Fibrinolytic Agents* / administration & dosage
  • Fibrinolytic Agents* / adverse effects
  • Humans
  • Hyperglycemia*
  • Intracranial Hemorrhages* / etiology
  • Ischemic Stroke* / drug therapy
  • Male
  • Middle Aged
  • Retrospective Studies
  • Tenecteplase* / administration & dosage
  • Thrombectomy* / methods
  • Thrombolytic Therapy / adverse effects
  • Thrombolytic Therapy / methods
  • Tissue Plasminogen Activator* / administration & dosage
  • Tissue Plasminogen Activator* / adverse effects
  • Tissue Plasminogen Activator* / pharmacology

Substances

  • Tissue Plasminogen Activator
  • Fibrinolytic Agents
  • Tenecteplase